Top Stories
Beren raised $300 million, comprising a $135-million equity financing, a $110-million loan agreement and a $55-million royalty deal, ahead of adrabetadex's Nov. 17 PDUFA date.
CEO Albert Bourla signals review of planned spending in the country, joining in the pharma pushback that's been building up over Berlin's policy proposals to lower health spending.
The biotech's ultra-sound mediated delivery technology is designed to enable durable gene expression across targeted tissues.
The expanded partnership will make use of Orionis's Allo‑Glue platform and AI‑driven discovery engine.
The biotech's lead programme is designed to block autoantibody-mediated activation of TSHR, the pathogenic driver of both Graves' disease and thyroid eye disease.
Conference News
BAAR, Switzerland--(BUSINESS WIRE)-- Stallergenes Greer, a global leader in allergy care, will present new clinical evidence and scientific advances in allergen immunotherapy (AIT) at the European Aca...
- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consist...
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to deve...
Over half (54%) of adults at risk of anaphylaxis admit they have been without their adrenaline auto-injector (AAI) when needed—and nearly 40% do not carry one regularly (n=1,238 ).1HCP survey data sug...
SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026 by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become...
